Premium
Apogee Therapeutics Inc (APGE)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subc... Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.43 | 1.38709677419 | 31 | 35.2 | 29.1 | 667773 | 31.10704953 | CS |
| 4 | -9.91 | -23.9719400097 | 41.34 | 42.14 | 29.1 | 617503 | 33.94521396 | CS |
| 12 | -17.34 | -35.5546442485 | 48.77 | 50.56 | 29.1 | 535299 | 39.20139425 | CS |
| 26 | -16.82 | -34.8601036269 | 48.25 | 63.5 | 29.1 | 493636 | 45.96024 | CS |
| 52 | -28.8 | -47.8167026399 | 60.23 | 72.29 | 29.1 | 502612 | 49.63749042 | CS |
| 156 | 9.93 | 46.1860465116 | 21.5 | 72.29 | 14.19 | 453230 | 42.6719617 | CS |
| 260 | 9.93 | 46.1860465116 | 21.5 | 72.29 | 14.19 | 453230 | 42.6719617 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
